SOLICITATION NOTICE
A -- Evaluation of Single Dose Protection Afforded by the Prophylactic HPV Vaccines
- Notice Date
- 12/23/2016
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N01CP71015-82
- Archive Date
- 1/24/2017
- Point of Contact
- Charles Park, Phone: 240-276-5896, Jill Johnson, Phone: 240-276-5395
- E-Mail Address
-
charles.park@nih.gov, jill.johnson2@nih.gov
(charles.park@nih.gov, jill.johnson2@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION WILL BE ISSUED ON A LATER DATE. The National Cancer Institute (NCI), National Institutes of Health (NIH) is seeking to support a prospective clinical trial aimed at evaluating the non-inferiority of 1 versus 2 doses of the HPV vaccines. The contract will also permit an additional extension to the follow-up of women in NCI's ongoing Costa Rica Vaccine Trial (CVT), which initially followed women for 10 years and will now extend that follow-up out to 15 years among a subset of participants. CVT showed similar HPV vaccine efficacy over four years among women who received one, two and three doses of the HPV16/18 vaccine, and stable antibody responses have been observed throughout the seven years of follow-up accrued to date in CVT, following up on these discoveries and further documenting the protection afforded by fewer doses could result in a monumental, global public health breakthrough. Thus, this new trial that will directly evaluate the protection afforded by single-dose and two-dose regimens of the prophylactic HPV vaccines. Continuation of the current cohort will document durability of antibody titers among women who received fewer doses. The services will be acquired through full and open competitive procedures under NAICS 541712. It is anticipated that one (1) cost reimbursement type contract will be awarded with a twelve (12) month base period and five 1-year options. The base period of performance will begin in 2017. The RFP will be available electronically at a later date and may be accessed through the FedBizOpps at www.fbo.gov. WE ENCOURAGE ALL RESPONSIBLE SOURCES, PARTICULARLY SMALL BUSINESSES, TO SUBMIT A PROPOSAL WHICH WILL BE CONSIDERED BY THE AGENCY. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile or email transmissions will be accepted. IT IS THE OFFERORS' RESPONSIBILITY TO MONITOR THE ABOVE-MENTIONED SITE FOR THE RELEASE OF THE SOLICITATION AND ANY AMENDMENTS.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N01CP71015-82/listing.html)
- Record
- SN04359980-W 20161225/161223233132-117128c826eafbd4dd9df56950bbc863 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |